|
|
 |
|
Viewing report
|
|
|
|
BRIC by BRIC, Building Russian Pharma
Informa Healthcare, April 2009, Pages: 16
The Russian pharmaceutical sector has to date suffered from poor liquidity, underdeveloped legislation and a paucity of home-grown talent. The development of the domestic industry is hamstrung by its inherent inability to innovate. Moreover, investors shy away from the types of risky projects needed for Russian pharma to take flight. The state's ambitious new strategy promises to change all that, but expect a long road ahead.
Key topics covered:
- Introduction to the Russian healthcare landscape
- DLO: Russia's state-restricted reimbursement programme; DLO driving the shift towards modern, expensive medicines
- Russia's import-oriented drugs market and the dominance of foreign medicines
- Top pharma companies in Russia
- Manufacturing without innovation; Russia's API manufacturing base
- Russian pharma's problems: inability to provide for the country's pharmaceutical needs and low innovative capacity
- 2020 vision: Russia's ambitious development strategy for the pharma industry over the next decade
- Is Russia ripe for clinical trials? Controversies; growth of the Russian clinical research market; corporate activity raises profile of Russia's CROs
- The financial crisis hits home in Russia
- Reform to shake up Russia's corporate pharma landscape
Customers who bought this item also bought
Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
Emerging Market for Clinical Trials in Russia - Curbs on New Drug Approval Timelines and Registration Fees Encourage the Emergence of a Major Global Player
Generic and Innovative Drugs Market in Russia and Ukraine 2011 - Comparative Analysis, Reimbursement Policies and Development Forecasts for 2011-2013
Russia Pharmaceutical Market Overview Pharma companies target Russia despite the challenges it presents
Emerging Market for Clinical Trials in Brazil - Improved Guidelines from ANVISA and CONEP are Shortening the Regulatory Approval Process and Advancing the Market
Emerging Clinical Trial Locations – Eastern Europe: Market Dynamics and the Changing Healthcare and Regulatory Environment
Global Clinical Trial Market (2007 - 2010) (Key Therapeutic Categories, Country Wise Metrics & Regulatory Approval Framework)
Strategic Analysis of the Russian Pharmaceutical Market
Opportunities in Emerging Markets - Central and Eastern Europe, Russia, and Ukraine
Emerging Market for Clinical Trials in China - Communication Problems and Unresolved Intellectual Property Issues Restrict Growth
|
|
|
|
